Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25281166 | 0.98 | HTT (0.56) | HTTTSHRCA12CA1CA2 | |
| Benzene SCHEMBL28272579 | 0.87 | JAK2 (0.55) | HTTCA12CA1CA2CA7 | |
| SCHEMBL7786056 | 0.85 | JAK2 (0.60) | HTTCA12CA1CA2CA7 | |
| SCHEMBL9357148 | 0.85 | JAK2 (0.56) | HTTCA12CA1CA2CA7 | |
| SCHEMBL29779548 | 0.85 | JAK2 (0.60) | HTTCA12CA1CA2CA7 | |
| SCHEMBL29746234 | 0.84 | CLCN2 (0.62) | HTTTSHRCA12CA1CA2 | |
| SCHEMBL29503131 | 0.83 | JAK2 (0.55) | HTTCA12CA1CA2CA7 | |
| SCHEMBL27249087 | 0.83 | JAK2 (0.59) | TSHRJAK2CLCN2KDM4EHPGD | |
| SCHEMBL10407472 | 0.83 | JAK2 (0.55) | HTTCA12CA1CA2CA7 | |
| SCHEMBL7835343 | 0.82 | TSHR (0.59) | HTTTSHRJAK2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396159-A | Synthesis method of 2,2' -biphenyl dicarboxylic acid compound | 湖南大学 | 2023-07-07 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| EP-3551634-B1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4126879-B1 | N-PHENYL SUBSTITUTED INDOLE DERIVATIVES AS MYT1 INHIBITORS FOR THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC (CA) | 2026-01-21 | — | — | EP | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| CN-115335378-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008157330-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1718639-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005085236-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, LIPC, PNLIP | HTT 4124/4885TSHR 3993/4885CA12 4115/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | HTT 3651/4885TSHR 400/4885CA12 3802/4885 |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | MGLL, LIPA, LIPC | HTT 3483/4885TSHR 2474/4885CA12 3715/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | HTT 1328/4885TSHR 172/4885CA12 2176/4885 |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | PLK1, CSNK1A1, CSNK1G1 | HTT 2044/4885TSHR 2951/4885CA12 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.